SUBSCRIBE
SUBSCRIBE

MASH

Pictured: 3D illustration of a damaged liver/iStoc
FDA
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.
March 18, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: Illustration of alphabetical letters ris
FDA
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
If you’re confused by the NASH versus MASH indication, you’re not alone.
March 15, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More
PRESS RELEASES
Press Releases
AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial
June 18, 2026
 · 
5 min read
Press Releases
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
June 10, 2026
 · 
11 min read
Press Releases
insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions
June 9, 2026
 · 
6 min read
Press Releases
GENFIT: NASHnext®, Powered by GENFIT’s Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 9, 2026
 · 
9 min read
Press Releases
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
June 8, 2026
 · 
5 min read
Press Releases
Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions
June 8, 2026
 · 
13 min read
Press Releases
Inipharm Initiates Dosing in 12-Week Proof-of-Concept Clinical Study in MASH With Its Oral HSD17B13 Inhibitor INI-822
June 2, 2026
 · 
3 min read
Press Releases
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
May 28, 2026
 · 
7 min read
Press Releases
Hepta’s Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH Patients
May 27, 2026
 · 
5 min read
Press Releases
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
May 27, 2026
 · 
7 min read
Press Releases
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
May 27, 2026
 · 
8 min read
Press Releases
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
May 27, 2026
 · 
15 min read
Press Releases
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
May 27, 2026
 · 
7 min read
Press Releases
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
 · 
7 min read
Press Releases
D&D Pharmatech Announces Positive 48-Week Histology Results for Zabopegdutide (DD01), Demonstrating Statistically Significant Fibrosis Improvement and MASH Resolution
May 27, 2026
 · 
6 min read
Press Releases
Inventiva Reports 2026 First Quarter Financial Information¹
May 26, 2026
 · 
10 min read
Press Releases
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
May 22, 2026
 · 
1 min read
Press Releases
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
May 20, 2026
 · 
10 min read
Press Releases
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
May 20, 2026
 · 
7 min read
Press Releases
Pilatus Biosciences to Present Preclinical Data Highlighting Novel Metabolic Checkpoint Therapy PLT012 at EASL Congress 2026
May 19, 2026
 · 
4 min read
Load More